Last reviewed · How we verify
Probiotic Arm
At a glance
| Generic name | Probiotic Arm |
|---|---|
| Also known as | (HEXBIO®) containing MCP® BCMC® strains, Lactobacillus rhamnosus, L. rhamnosus GR-1 and L. reuteri RC-14, VSL#3, Bio 25 |
| Sponsor | Al-Mustansiriyah University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of L. Reuteri LM1063 on Sleep Health Improvement (NA)
- Effect of Probiotic Supplementation on Endothelial Function II (NA)
- Probiotic (LGG) for Veterans With PTSD (PHASE2)
- Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents (NA)
- A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals (NA)
- Efficacy of Symprove Probiotics in Coeliac Disease (NA)
- Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis (NA)
- Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic Arm CI brief — competitive landscape report
- Probiotic Arm updates RSS · CI watch RSS
- Al-Mustansiriyah University portfolio CI